Added value of pharmacogenetic testing in predicting statin response: Results from the REGRESS trial

Van Der Baan, F.H.; Knol, M.J.; Maitland-Van Der Zee, A.H.; Regieli, J.J.; Van Iperen, E.P.A.; Egberts, A.C.G.; Klungel, O.H.; Grobbee, D.E.; Jukema, J.W.

doi:https://doi.org/10.1038/tpj.2012.12

Added value of pharmacogenetic testing in predicting statin response: Results from the REGRESS trial

DSpace/Manakin Repository

Added value of pharmacogenetic testing in predicting statin response: Results from the REGRESS trial

Van Der Baan, F.H.; Knol, M.J.; Maitland-Van Der Zee, A.H.; Regieli, J.J.; Van Iperen, E.P.A.; Egberts, A.C.G.; Klungel, O.H.; Grobbee, D.E.; Jukema, J.W.

(2013) The Pharmacogenomics Journal, volume 13, issue 4, pp. 318 - 324

(Article)

Abstract

It was investigated whether pharmacogenetic factors, both as single polymorphism and as gene-gene interactions, have an added value over non-genetic factors in predicting statin response. Five common polymorphisms were selected in apolipoprotein E, angiotensin-converting enzyme, hepatic lipase and toll-like receptor 4. Linear regression models were built and compared on R2to ... read more

Download/Full Text

Embargo until January 01 2050

Keywords: Gene-gene interactions, Genotype, Pharmacogenetics, Pravastatin response, apolipoprotein E, dipeptidyl carboxypeptidase, liver triacylglycerol lipase, low density lipoprotein cholesterol, placebo, pravastatin, toll like receptor 4, adult, angiotensin converting enzyme gene, apolipoprotein E gene, article, controlled study, coronary artery atherosclerosis, double blind procedure, drug response, female, gene interaction, genetic polymorphism, genetic screening, hepatic lipase gene, heredity, human, major clinical study, male, pharmacogenetics, prediction, priority journal, randomized controlled trial, toll like receptor 4 gene

DOI: https://doi.org/10.1038/tpj.2012.12

ISSN: 1470-269X

Publisher: Nature Publishing Group

(Peer reviewed)

See more statistics about this item